Literature DB >> 11508671

Clinical significance of elevated alpha-fetoprotein in adults and children.

R Kashyap1, A Jain, M Nalesnik, B Carr, J Barnes, H E Vargas, J Rakela, J Fung.   

Abstract

The aim of the current study is to identify underlying pathology associated with elevated serum alpha-fetoprotein (AFP; >20 ng/ml) among patients referred to a tertiary-care academic medical center with emphasis in liver diseases, hepatobiliary surgery, and liver transplantation. From May 1992 to April 1997, 386 patients (320 adults and 66 children) with elevated AFP (>20 ng/ml) were identified from the Medical Archival System (MARS) database at the University of Pittsburgh Medical Center. The medical records from all these patients were retrospectively reviewed. Radiological, pathological, and biochemical profiles were obtained at the time of documented elevated AFP. These patients included: 218 adults with malignancies, 102 adults without malignancies, 18 children and infants with malignancies, and 48 children and infants without malignancies. Thirty-two percent of adults were found to have raised AFP with liver disease and without hepatocellular carcinoma and 78% had some type of malignancy, predominantly hepatocellular carcinoma. Seventy-three percent of infants and children had elevated AFP without malignancy. Based on our findings, we recommend that all patients (adults, infants and children) with raised AFP of >20 ng/ml should undergo thorough evaluation to rule out malignant disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508671     DOI: 10.1023/a:1010605621406

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

Review 1.  Human alphafetoprotein 1956-1978.

Authors:  M Adinolfi
Journal:  Adv Hum Genet       Date:  1979

2.  Embryonal serum alpha-globulin in cancer patients: diagnostic value.

Authors:  G I Abelev; I V Assecritova; N A Kraevsky; S D Perova; N I Perevodchikova
Journal:  Int J Cancer       Date:  1967-09-15       Impact factor: 7.396

Review 3.  Hepatocellular carcinoma.

Authors:  M C Kew
Journal:  Postgrad Med J       Date:  1983       Impact factor: 2.401

4.  A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group.

Authors:  J Rakela; J W Mosley; V M Edwards; S Govindarajan; E Alpert
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

5.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

6.  Maternal serum alpha-fetoprotein in fetal anal atresia and other gastro-intestinal obstructions.

Authors:  M Van Rijn; G C Christaens; A M Hagenaars; G H Visser
Journal:  Prenat Diagn       Date:  1998-09       Impact factor: 3.050

7.  Clinical significance of serum alpha-fetoprotein in patients with liver cirrhosis.

Authors:  R Furukawa; H Tajima; K Nakata; K Kono; T Muro; A Sato; K Kawahara; N Ishii; Y Kusumoto; T Munehisa
Journal:  Tumour Biol       Date:  1984

8.  Transport of proteins across the human placenta.

Authors:  A Malek; R Sager; H Schneider
Journal:  Am J Reprod Immunol       Date:  1998-11       Impact factor: 3.886

9.  Comparison of various assays for detection of AFP in differentiating patients with primary hepatocellular carcinoma from controls.

Authors:  S H Chan; S H Heng; S L Yo; C J Oon
Journal:  J Clin Pathol       Date:  1980-08       Impact factor: 3.411

10.  Alpha-fetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis.

Authors:  E Alpert; E R Feller
Journal:  Gastroenterology       Date:  1978-05       Impact factor: 22.682

View more
  7 in total

1.  Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken.

Authors:  Vaneet Jearth; Prachi S Patil; Shaesta Mehta; Sridhar Sundaram; Vishal Seth; Mahesh Goel; Shraddha Patkar; Munita Bal; Vidya Rao
Journal:  J Clin Exp Hepatol       Date:  2021-11-16

2.  Diagnosis of hepatocellular carcinoma.

Authors:  Eldad S Bialecki; Adrian M Di Bisceglie
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

3.  Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma.

Authors:  Chang-Yi Lu; Shih-Ya Chen; Hui-Ling Peng; Pu-Yeh Kan; Wan-Chi Chang; Chia-Jui Yen
Journal:  Oncotarget       Date:  2017-01-24

4.  Predictors of post-hepatectomy liver failure in patients undergoing extensive liver resections for hepatocellular carcinoma.

Authors:  Ken Min Chin; John Carson Allen; Jin Yao Teo; Juinn Huar Kam; Ek Khoon Tan; Yexin Koh; Kim Poh Brian Goh; Peng Chung Cheow; Prema Raj; Kah Hoe Pierce Chow; Yaw Fui Alexander Chung; London Lucien Ooi; Chung Yip Chan; Ser Yee Lee
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2018-08-31

5.  HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.

Authors:  A M Attallah; M M Omran; A A Attallah; S O Abdallah; K Farid; H Darwish; I El-Dosoky; Y M Shaker
Journal:  Br J Cancer       Date:  2013-08-27       Impact factor: 7.640

6.  Inhibited effects of CAPE-pNO2 on cervical carcinoma in vivo and in vitro and its detected metabolites.

Authors:  Xiaofang Yao; Hao Tang; Qiao Ren; Xiaoyan Zhao; Hua Zuo; Zhubo Li
Journal:  Oncotarget       Date:  2017-10-07

7.  Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics.

Authors:  Jr-Shiang Shiu; Ming-Ju Hsieh; Hui-Ling Chiou; Hsiang-Ling Wang; Chao-Bin Yeh; Shun-Fa Yang; Ying-Erh Chou
Journal:  Int J Med Sci       Date:  2018-08-10       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.